与传统的ERCP相比，胆道子镜辅助的无射线内镜下胆管取石及引流术，即“一步法”内镜下治疗SAC的治疗方式显示了良好的结果，适合SAC的ICU床旁治疗，明显提高患者生存率。因此，该研究为急性重症胆管炎患者提供了一种可行的床旁无射线内镜下治疗的新方法。

近日，消化领域顶级期刊《胃肠病学》（ Gastroenterology ，IF=25.7）以 封面文章 的形式发表了上海交通大学医学院附属仁济医院 马雄教 授课题组最新研究成果。题为 “Gut Microbiota-Derived Butyrate ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary ...

The European Commission has conditionally approved the marketing application submitted by Ipsen for Iqirvo (elafibranor) 80mg ...

The global market for primary sclerosing cholangitis (PSC) is on an impressive growth trajectory, with forecasts estimating a ...

Ipsen (IPSEY) announced the European Commission has conditionally approved Iqirvo 80mg tablets for the treatment of primary biliary ...

The U.S. Food and Drug Administration's staff on Wednesday raised concerns over the efficacy of Intercept Pharmaceuticals' ...

Obeticholic acid had been awarded accelerated approval by the FDA in May 2016 as a second-line treatment for PBC patients not ...

Following a meeting with the FDA’s Gastrointestinal Drug Advisory Committee Friday, the future of Intercept’s rare liver ...

European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver diseaseApproval follows posit ...

Families are increasingly turning down requests to donate a relative's organs, sometimes because their loved one's wishes ...